Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
New Study Offers Insight into Alzheimer’s Disease Research Landscape
Posted on September 9th, 2019 by Tom Williams
Pharma R&D
The sixth leading cause of death in the U.S., and estimated to affect approximately 45 million people worldwide, Alzheimer’s is a progressive brain disease that causes memory loss and overall mental deterioration. Coinciding with World Alzheimer’s Month, Elsevier just released a report (which you can download here) analyzing Alzheimer’s research spanning the last 50 years in order to present a comprehensive overview of the research landscape for this irreversible condition.
(more…)Elsevier research will be featured at upcoming Safety Pharmacology Society meeting
Posted on September 4th, 2019 by Xuanyan Xu
Pharma R&D
The 2019 Safety Pharmacology Society meeting will be in Barcelona from September 23-26, and the event is bringing together industry professionals to share best practices, enjoy networking opportunities, hear keynote speeches from thought leaders, and learn about hot research topics from experts in the field.
(more…)Cannibidiol is All the Rage – Is Pharma Getting in on the CBD Craze?
Posted on August 14th, 2019 by Christy J. Wilson
Pharma R&D
Few substances on earth have been surrounded by more confusion than marijuana. Harmless plant or illicit drug? Medicinal or recreational? Legal or illegal (or partially legal)? And what should we make of all these things associated with marijuana, like hemp and CBD oil?
(more…)The Beneficial Impacts of Real-World Evidence in Drug Development
Posted on August 1st, 2019 by Xuanyan Xu
Pharma R&D
Advances in technology, increased investment in digital solutions and the creation of more powerful analytics are all contributing to a growing interest in utilizing real-world evidence (RWE) in drug discovery & development. Following up on my previous post that goes into detail on what RWE is and why the industry is increasingly drawn to it, I now want to discuss its role and impact in the drug development life cycle.
(more…)Why is the Pharma Industry Buzzing About Real-World Evidence?
Posted on July 30th, 2019 by Xuanyan Xu
Pharma R&D
You have almost certainly heard the terms Real-World Data (RWD) and Real-World Evidence (RWE) – but are you still unsure about exactly what these things are and why they’re important? Let’s break it down.
(more…)Global Dominance in AI? China’s Got a Plan For That
Posted on July 9th, 2019 by Xuanyan Xu
Pharma R&D
Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.
(more…)About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.
